N-terminal and C-terminal cytosine deaminase domain of APOBEC3G inhibit hepatitis B virus replication

Yan-Chang Lei, Yong-Jun Tian, Hong-Hui Ding, Bao-Ju Wang, Yan Yang, You-Hua Hao, Xi-Ping Zhao, Meng-Ji Lu, Fei-Li Gong, Dong-Liang Yang

Abstract

AIM: To investigate the effect of human apolipoprotein B mRNA-editing enzyme catalytic-polypeptide 3G (APOBEC3G) and its N-terminal or C-terminal cytosine deaminase domain-mediated antiviral activity against hepatitis B virus (HBV) in vitro and in vivo.

METHODS: The mammalian hepatoma cells HepG2 and HuH7 were cotransfected with APOBEC3G and its N-terminal or C-terminal cytosine deaminase domain expression vector and 1.3-fold-overlength HBV DNA as well as the linear monomeric HBV of genotype B and C. For in vivo study, an HBV vector-based mouse model was used in which APOBEC3G and its N-terminal or C-terminal cytosine deaminase domain expression vectors were co-delivered with 1.3-fold-overlength HBV DNA via high-volume tail vein injection. Levels of hepatitis B virus surface antigen (HBsAg) and hepatitis B virus e antigen (HBeAg) in the media of the transfected cells and in the sera of mice were determined by ELISA.

The expression of hepatitis B virus core antigen (HBcAg) in the transfected cells was determined by Western blot analysis. Core-associated HBV DNA was examined by Southern blot analysis. Levels of HBV DNA in the sera of mice as well as HBV core-associated RNA in the liver of mice were determined by quantitative PCR and quantitative RT-PCR analysis, respectively.

RESULTS: Human APOBEC3G exerted an anti-HBV activity in a dose-dependent manner in HepG2 cells, and comparable suppressive effects were observed on genotype B and C as that of genotype A. Interestingly, the N-terminal or C-terminal cytosine deaminase domain alone could also inhibit HBV replication in HepG2 cells as well as Huh7 cells. Consistent with in vitro results, the levels of HBsAg in the sera of mice were dramatically decreased, with more than 50 times decrease in the levels of serum HBV DNA and core-associated RNA in the liver of mice treated with APOBEC3G and its N-terminal or C-terminal cytosine deaminase domain as compared to the controls.

CONCLUSION: Our findings provide probably the first evidence showing that APOBEC3G and its N-terminal or C-terminal cytosine deaminase domain could suppress HBV replication in vitro and in vivo.

© 2006 The WJG Press. All rights reserved.

Key words: Cytosine deaminase domain; Apolipoprotein B mRNA-editing enzyme catalytic-polypeptide 3G; Hepatitis B virus; Antiviral therapy

Lei YC, Tian YJ, Ding HH, Wang BJ, Yang Y, Hao YH, Zhao XP, Lu MJ, Gong FL, Yang DL. N-terminal and C-terminal cytosine deaminase domain of APOBEC3G inhibit hepatitis B virus replication. World J Gastroenterol 2006; 12(46): 7488-7496

http://www.wjgnet.com/1007-9327/12/7488.asp

INTRODUCTION

Hepatitis B virus (HBV) infects more than 350 million people worldwide and is a leading cause of end-stage liver disease and of hepatocellular carcinoma[4]. HBV is non-cytotoxic for hepatocytes; however, most newly HBV-
infected adult patients develop acute hepatitis because of a strong immune response that clears HBV from the liver, whereas approximately 5% of newly HBV-infected adult patients generate insufficient immunity and become chronically infected[1-2]. HBV and other hepadnaviruses replicate their partially double-stranded DNA genome within cytoplasmic core particles by reverse transcription of encapsidated pregenomic RNA and thus are related to retroviruses[3].

The cytidine deaminase APOBEC3G (A3G), which is encoded within a cluster of seven related editing enzymes (APOBEC3A-G) on chromosome 22, provides a broad innate immunity against exogenous and endogenous retroelements[4-10]. It has been shown that the propagation of HIV-1 strains lacking the accessory protein virion infectivity factor (VIF) is suppressed in non-permissive cells due to expression of the cytidine deaminase APOBEC3G[5,11]. Encapsidated into the retroviral particle, APOBEC3G induces massive C→U deamination of single-stranded retroviral DNA, resulting in DNA degradation or lethal G→A hypermutation[5,11]. HIV overcomes this innate defense barrier in T-cells with the help of the HIV-encoded VIF protein that specifically targets A3G to proteosomal degradation[11-13]. In addition, APOBEC3F (another cytidine deaminase of APOBEC family) is a potent retroviral Restrictor, but its activity, unlike that of APOBEC3G, is partially resistant to HIV-1 VIF and results in retroviral hypermutation. Moreover, APOBEC3F and APOBEC3G appear to be coordinately expressed in a wide range of human tissues and are independently able to inhibit retroviral infection. Thus, APOBEC3F and APOBEC3G are likely to function alongside one another in the provision of an innate immune defense, with APOBEC3F functioning as the major contributor to HIV-1 hypermutation in vivo[19].

Recent evidence suggests that some of the HIV restriction exerted by A3G may be independent of its cytidine deaminase activity[6-10]. Interestingly, APOBEC3G can also interfere with the HBV life cycle in co-transfected cells[19,20]. However, reduced levels of encapsidated viral pgRNA rather than extensive editing was found to be the major contributing factor[19], APOBEC3G-mediated editing did occur but was only detected in a minority of clones produced in the transfected HepG2 hepatoma cells[20]. In addition, the C-terminal cytosine deaminase domain catalytically inactive APOBEC3G derivatives no longer inhibited VIF-defective HIV-1 but did conserve wild-type levels of activity on HBV[19]. As a result, the mechanisms of APOBEC3G blocking HBV production are unclear.

A previous study shows that APOBEC family members contain a domain structure characteristic of cytidine deaminases[21]. A short α-helical domain is followed by a catalytic domain (CD), a short linker peptide and a pseudocatalytic domain (PCD). In APOBEC3G, the entire unit is duplicated to form the domain structure helix1-CD1-linker1-PCD1-helix2-CD2-linker2-PCD2. Each catalytic domain contains the conserved motif H-X-E(X)27-28-P-C-X-X-C in which the His and Cys residues coordinate Zn2+ and the Glu serves as a proton shuttle in the deamination reaction[22]. Based on the molecular structure of APOBEC3G and recent research results, we speculated that the N-terminal or C-terminal cytidine deaminase domain of APOBEC3G could also display HBV inhibition activity.

In the present study, we performed a detailed analysis of the inhibitory effect of APOBEC3G and its N-terminal or C-terminal cytosine deaminase domain on hepatitis B virus replication in cell culture and in an HBV vector-based mouse model.

MATERIALS AND METHODS

Plasmid constructs

For construct expression vectors coding for human APOBEC3G (pXFA3G), total RNA was extracted from the peripheral blood mononuclear cells (PBMCs). RT-PCR amplification of human APOBEC3G sequence was carried out using forward primer 5'-CCGAATTCACAGCTCATTCAAGCCTCAGAAAACACGAC-3' and reverse primer 5'-CAGAGTTCTGGCCTTCATGGAGACTG-3'. The PCR product was cloned into EcoRI/HindIII restriction sites of the CMV-driven expression vector fused with a hemagglutinin fusion epitope tag at its N-terminal end (pXF3H) to construct APOBEC3G expression plasmid (p3A3G). p3A3G was digested with EcoRI/BamHI and EcoRI/BamHI/HindIII, these fragments were inserted into pXF3H to construct the N-terminal and C-terminal cytosine deaminase domain expression plasmids (pXFN3A3G and pXFC3A3G), respectively. p3A3G was digested with EcoRI/BglII, and used for the construction of the N-terminal region of APOBEC3G which did not contain any cytosine deaminase domain plasmid (pXFA3G). pCMV: CMV promoter; CD1: N-terminal cytosine deaminase domain; CD2: C-terminal cytosine deaminase domain.
genotype B and genotype C with \(5\alpha\)P ends have been constructed previously in our laboratory.

**Cell culture, transfection and harvesting**

HepG2 and HuH7 cells were grown in Dulbecco’s modified Eagle medium (DMEM) supplemented with 100 mL/L fetal calf serum (Invitrogen, CA, USA) at 37°C in a humidified atmosphere containing 50 mL/L CO\(_2\). The cells were plated at a density of 4.5 × 10\(^4\) cells per well in 6-well plates 18 h prior to transfection. Transfection of cells was performed with lipofectamine 2000 (Invitrogen, USA) following the manufacturer’s guidelines. On d 3 after transfection, the cells were removed from the culture dish via treatment with trypsin-EDTA, resuspended in culture medium, washed with phosphate-buffered saline (PBS), pelleted, and resuspended in 1 mL chilled lysis buffer (140 mmol/L NaCl, 1.5 mmol/L MgCl\(_2\), 50 mmol/L Tris-HCl [pH 8.0]) containing 5 mL/L NP-40. Nuclei were removed via centrifugation for 5 min at 2000 r/min in an eppendorf centrifuge, and the supernatant was clarified by centrifugation for another 5 min at 14 000 g.

**HBV vector-based mouse model**

For the in vivo experiments, 6 to 8-wk-old female BALB/c mice were used. A total of 30 mice were randomly divided into 5 groups (6 mice/group). Replication-competent pHBV1.3 (10 \(\mu\)g) and APOBEC3G and its N-terminal or C-terminal cytosine deaminase domain expression vectors (10 \(\mu\)g) or pXF3H (10 \(\mu\)g) control plasmid DNA were co-injected into the tail vein of mice in a volume of Ringer’s injection equivalent to 9% of the mouse body weight\(^{23,24}\), the total volume was delivered within 5 s. The mice sera were collected at an indicated time after hydrodynamic injection, and secreted hepatitis B virus surface antigen (HBsAg) levels and HBV DNA content were measured. All mouse experiments were carried out according to the guidelines established by the Institutional Animal Care and Use Committee at the Tongji Medical College, Huazhong University of Science and Technology.

**HBsAg and HBeAg assays and Western blot analysis**

Levels of HBsAg and HBeAg in the media of the transfected cells, and in the sera (1:100 dilution) of the treated mice were determined using an ELISA kit (Shanghai Shiyue Kehua Company, China). For Western blot analysis, cytoplasmic lysates were incubated with 1 vol 2 × loading buffer containing 100 mL/L beta-mercaptoethanol for 10 min at 95°C before loading on a 125 g/L SDS-PAGE. Proteins were transferred onto a nitrocellulose membrane via electroblotting. The membranes were incubated with HBV core-specific rabbit antisera (Santa Cluz, USA) or with anti-hemagglutinin fusion epitope monoclonal antibody (Santa Cluz, USA), followed by horseradish peroxidase-conjugated mouse anti-rabbit antibody. Proteins were visualized by Enhanced Chemiluminescene (Roche, Germany).

**HBV DNA purification and analysis**

The method for purification of cytoplasmic core-associated HBV DNA was adapted from Pugh et al\(^{26}\). Briefly, HepG2 cells were disrupted in lysis buffer (100 mmol/L Tris-HCl, pH 8.0, 2 mL/L NP-40). The cell lysate was clarified by centrifugation at 13 000 g for 1 min to pellet nuclei and insoluble material. The supernatant was adjusted to 6 mmol/L MgOAC\(_2\) and incubated for 2 h at 37°C with 200 \(\mu\)g/mL DNase I and 100 \(\mu\)g/mL RNase A. Following digestion, the lysate was centrifuged for 1 min at 13 000 g. The supernatant was incubated for 1 h at 55°C after addition of 10 mmol/L EDTA, 10 g/L SDS, 100 mmol/L NaCl and 200 \(\mu\)g/mL proteinase K. Finally, the sample was extracted with phenol-chloroform. The DNA was ethanol precipitated, resuspended in TE at pH 8 (10 mmol/L Tris-HCl, pH 7.5; 1 mmol/L EDTA) and digested with 100 \(\mu\)g/mL RNase A for 30 min at 37°C. The purified DNA was subjected to Southern blot analysis. DNA samples were loaded onto 13 g/L agarose gels, blotted onto nylon membranes, and probed with a Dig-labeled full-length HBV genome in EasyHyb hybridization solution (Roche, Germany).

For quantitative PCR, 100 \(\mu\)L of mouse serum was adjusted to 6 mmol/L MgOAC\(_2\) and incubated for 2 h at 37°C with 200 \(\mu\)g/mL DNase I and 100 \(\mu\)g/mL RNase A. Following proteinase K digestion, the sample was extracted with phenol-chloroform. HBV DNA levels were analyzed with the Light Cycle real-time PCR system (Roche, Germany), using the primer sequences as follows: 5’-TCA-CATATACCGAGAGTC-3’ (nt231-248, forward) and 5’-AGCAACAGGGAGATACA-3’ (nt569-552, reverse). The pHBV1.0 vector containing the full-length HBV genome was used as a standard curve to calculate HBV copies per milliliter of serum.

**RNA isolation and analysis**

For quantitative RT-PCR, approximately 20 mg of liver tissue was obtained from each mouse for total RNA extraction with RNeasy Total RNA kit (Qiagen, Germany), according to the manufacturer’s protocol. cDNA was synthesized from 2 \(\mu\)g of total RNA with oligo(dT)\(_{18}\) primer in a total volume of 20 \(\mu\)L. Quantitative RT-PCR was performed with the Light Cycler real-time PCR system (Roche, Germany). The PCR primers were as follows: GAPDH, 5’-GGTGTTCTCCTGCGACTTCA-3’ (forward) and 5’-GTTGTGTCAGGGTCTTCTA-3’ (reverse); HBV, 5’-TCACAATACCGCAGAGTC-3’ (nt231-248, forward) and 5’-AGCAACAGGGAGATACA-3’ (nt569-552, reverse). A standard curve was constructed by the simultaneous amplification of serial dilutions of the expression plasmid encoding HBV used as templates. Target cDNAs were normalized to the endogenous RNA levels of the DAPDH. Quantitative amplification was carried out using the SYBR Green kit (Invitrogen, USA). Gene expression was determined using the relative quantification: \(\Delta\Delta C_t = (C_{\text{HBV}}-C_{\text{GAPDH}})/C_{\text{Test}} - (C_{\text{HBV}}-C_{\text{GAPDH}})/C_{\text{Control}}\). \(C_t\) is the fractional cycle number that reaches a fixed threshold, \(C_{\text{Test}}\) is the test of interest, and \(C_{\text{Control}}\) is the reference control (RNA from control group). \(\Delta C_t\) is the difference between gene expression in the treated cells and the reference control cells. The fold increase was calculated using \(2^{\Delta\Delta C_t}\).

**RESULTS**

**Inhibitory effect of APOBEC3G on HBV DNA replication in cell culture**

Various amounts of a CMV-driven expression vector
Suppression of the replication of HBV clinical isolates of different genotypes by APOBEC3G

Based on sequence divergence, HBV can be classified into at least 8 genotypes. These results, in agreement with our and other’s results, showed that APOBEC3G inhibited the replication of a laboratory clone of genotype A (subtype ayw). Further testing concerned whether or not APOBEC3G could also inhibit the replication of HBV with different genotypes from clinical isolates. As genotypes B and C are the most prevalent genotypes in China, this study mainly focused on these 2 genotypes. A previous study has demonstrated that linear monomeric HBV genomes with $S^p\perp 1$ ends can initiate a full replication cycle, leading to viral replication and antigen expression.

In order to examine the effect of APOBEC3G on different genotypes of clinical isolates, a full-length HBV genome of genotype B or C was amplified from the patient’s serum by PCR and cloned into pUC19 vector. After digestion with $S^p\perp 1$, the linear monomeric HBV genomes were transfected into HepG2 cells with APOBEC3G expression plasmid (pA3G) or the control plasmid (pXF3H). Three days after transfection, HBV core-associated DNA was analyzed by Southern blot. As shown in Figure 3, pA3G could also inhibit the replication of HBV genotypes B and C from clinical isolates to a similar extent as on genotype A.

Inhibitory effect of N-terminal and C-terminal cytosine deaminase domain of APOBEC3G on HBV DNA replication in cell culture

APOBEC family members contain a domain structure characteristic of cytidine deaminases. A short a-helical domain is followed by a catalytic domain (CD), a short linker peptide and a pseudocatalytic domain (PCD). In APOBEC3G, the entire unit is duplicated to form the domain structure helix1-CD1-linker1-PCD1-helix2-CD2-linker2-PCD2. Each catalytic domain contains the characteristic of cytidine deaminases.

APOBEC family members contain a domain structure characteristic of cytidine deaminases. A short a-helical domain is followed by a catalytic domain (CD), a short linker peptide and a pseudocatalytic domain (PCD). In APOBEC3G, the entire unit is duplicated to form the domain structure helix1-CD1-linker1-PCD1-helix2-CD2-linker2-PCD2. Each catalytic domain contains the conserved motif H-X-E-(X)27-28-P-C-X-X-C in which the His and Cys residues coordinate Zn$^{2+}$ and the Glu serves as a proton shuttle in the deamination reaction.
and with pCMV-LacZ to normalize for transfection efficiency. HBsAg and HBeAg levels were determined by ELISA. As expected, N-terminal or C-terminal cytosine deaminase domain of APOBEC3G expression plasmid (pNA3g and pCA3g) could also reduce the level of replicative HBV intermediates and HBsAg and HBeAg levels in the media of co-transfected HepG2 cells, while the N-terminal region of APOBEC3G, which did not contain any cytosine deaminase domain (pEA3G), had no inhibitory effect on HBV production, and the same results were observed in another human hepatoma cell line HuH7 (Figures 4A and 4B). In a series of six independent experiments, the expression of A3G and its N-terminal or C-terminal cytosine deaminase domain, but not of pEA3G, resulted in a consistent decrease of secreted HBsAg and HBeAg even after correction for transfection efficiency by determination of the co-transfected galactosidase (Figure 4C). Compared with the empty vector control and normalized to the amount of secreted HBsAg, the N-terminal or C-terminal cytosine deaminase domain decreased the formation of intracellular HBV-replicative intermediates in this series to approximately 60% and thus achieved a similar level of inhibition as A3G (Figure 4D).

In all of these experiments, pEA3G showed no apparent inhibition of HBV replication (Figure 4D). However, Western blot analysis, using the polyclonal anti-HBV core antibody, indicated that the levels of core protein were unaffected by APOBEC3G and its N-terminal or C-terminal cytosine deaminase domain (Figure 4E).

**Inhibition of HBV replication in mice by N-terminal or C-terminal cytosine deaminase domain of APOBEC3G**

To examine whether the N-terminal or the C-terminal cytosine deaminase domain of APOBEC3G could also display HBV inhibitory activity, we speculated that the N-terminal or C-terminal cytosine deaminase domain of APOBEC3G could also display HBV inhibitory activity.

To verify this hypothesis, APOBEC3G and its N-terminal or C-terminal cytosine deaminase domain expression plasmids were co-transfected with replication-competent 1.3-fold-overlength HBV DNA into HepG2 and HuH7 cells, and with pCMV-LacZ to normalize for the transfection efficiency. HBV core-associated viral DNA was prepared 3 d after transfection and analyzed by Southern blotting. HBsAg and HBeAg levels were determined by ELISA. As expected, N-terminal or C-terminal cytosine deaminase domain of APOBEC3G expression plasmid (pNA3g and pCA3g) could also reduce the level of replicative HBV intermediates and HBsAg and HBeAg levels in the media of co-transfected HepG2 cells, while the N-terminal region of APOBEC3G, which did not contain any cytosine deaminase domain (pEA3G), had no inhibitory effect on HBV production, and the same results were observed in another human hepatoma cell line HuH7 (Figures 4A and 4B). In a series of six independent experiments, the expression of A3G and its N-terminal or C-terminal cytosine deaminase domain, but not of pEA3G, resulted in a consistent decrease of secreted HBsAg and HBeAg even after correction for transfection efficiency by determination of the co-transfected galactosidase (Figure 4C). Compared with the empty vector control and normalized to the amount of secreted HBsAg, the N-terminal or C-terminal cytosine deaminase domain decreased the formation of intracellular HBV-replicative intermediates in this series to approximately 60% and thus achieved a similar level of inhibition as A3G (Figure 4D).

In all of these experiments, pEA3G showed no apparent inhibition of HBV replication (Figure 4D). However, Western blot analysis, using the polyclonal anti-HBV core antibody, indicated that the levels of core protein were unaffected by APOBEC3G and its N-terminal or C-terminal cytosine deaminase domain (Figure 4E).

**DISCUSSION**

Our study describes the inhibitory effects of human APOBEC3G and its N-terminal or C-terminal cytosine deaminase domain on HBV DNA production in mammalian hepatoma cells as well as in HBV vector-based mouse model. Our data confirm and extend the recent results by Turelli et al. [32] who reported A3G-mediated inhibition of HBV DNA production in human...
Figure 4  Inhibitory effect of the N-terminal and C-terminal cytosine deaminase domain on HBV production in the co-transfected cells. (A and B) Human hepatoma HepG2 and HuH7 cells were transiently co-transfected with the pHBV1.3 and CMV-driven expression vector encoding A3G and its N-terminal or C-terminal cytosine deaminase domain or with the empty vector pXF3H and pCMV-LacZ using Lipofectamine 2000 reagents. The cells were harvested 3 d after transfection. HBV core-associated viral DNA was prepared from nuclease-treated cytoplasmic lysates. Viral replicative DNA intermediates were analyzed by Southern blotting using a Dig-labeled full-length HBV DNA probe. (C) HBsAg and HBeAg levels were determined in the media of co-transfected HepG2 cells by ELISA, normalized to the activity of co-transfected β-galactosidase in the cell lysates. The mean ± SE of six independent experiments is shown (error bar indicates standard error). (D) The hybridized HBV DNA from the replicative intermediates was quantified by radiophosphorimaging, normalized to the amount of secreted HBsAg (normalized for co-transfected β-galactosidase activity) and calculated relative to the empty vector control (pXF3H). The mean ± SE of six independent experiments is shown. (E) Anti-HA monoclonal antibody for Western blot analysis of cytoplasmic extracts from HepG2 cells co-transfected with the indicated plasmids. Numbers at the end or top of the lines indicate the amount of transfected plasmid DNA in micrograms. pXF3H: empty vector; pA3G: APOBEC3G expression plasmids; pNA3G: N-terminal cytosine deaminase domain of APOBEC3G expression plasmids; pCA3G: C-terminal cytosine deaminase domain of APOBEC3G expression plasmids; pEA3G: N-terminal region of APOBEC3G which does not contain any cytosine deaminase domain plasmid; HBV: hepatitis B virus; RC: relaxed circular DNA; SS: single-stranded DNA; HBcAg: hepatitis B virus core antigen; HBsAg: hepatitis B virus surface antigen; HBeAg: hepatitis B virus e antigen.
HuH-7 hepatoma cells. Previous studies suggested that G-to-A hypermutation could influence HBV pathogenesis. Specific G-to-A changes yielded HBeAg-negative HBV variants, often isolated from patients with acute fulminant hepatitis, as well as HBV vaccine escape mutants\cite{31,32}. However, there is no evidence so far that APOBEC3G-induced lethal hypermutation represents an important innate defense mechanism down-regulating hepadnavirus production.

APOBEC3G site-directed mutation experiments showed that both the N- and the C-terminal cytosine deaminase domains were required for inhibiting the infectivity of HIV-based retroviruses\cite{19,20}, and the C-terminal cytosine deaminase domain of APOBEC3G governed the catalytic activity and the retroviral hypermutation specificity, while the N-terminal deaminase domain was to perform other aspects of retroviral restriction specificity, while the N-terminal deaminase domain was to perform other aspects of retroviral restriction specificity, while the N-terminal deaminase domain was to perform other aspects of retroviral restriction specificity, while the N-terminal deaminase domain was to perform other aspects of retroviral restriction specificity, while the N-terminal deaminase domain was to perform other aspects of retroviral restriction specificity, while the N-terminal deaminase domain was to perform other aspects of retroviral restriction.

Although APOBEC3G could inhibit HBV replication, extensive editing was not found to be the major contributing factor\cite{23,30}. Each catalytic domain contains the conserved motif in which the His and Cys residues coordinate Zn\cite{22} and the Glu serves as a proton shuttle in the deamination reaction\cite{22}. In this study, we found the N-terminal and C-terminal cytosine deaminase domain of APOBEC3G could inhibit HBV DNA replication and gene expression in cell culture and the HBV vector-based mouse model. Together with the fact that catalytically inactive APOBEC3G derivatives no longer inhibited VIF-defective HIV-1 but did conserve wild-type levels of activity on HBV, confirming the hypothesis that APOBEC3G might act on HBV and retroviruses through different mechanisms. As a result, we speculated that the RNA binding activity might play a role in these processes, for example, APOBEC3G might bind to the pregenome RNA or interfere with the binding of the ε subunit and RT domain of HBV DNA polymerase, but this needs further investigation.

Given the high heterogeneity of HBV sequences, HBV can be classified into 8 genotypes according to the sequence divergence\cite{28}. Our results and other group showed that APOBEC3G inhibited the replication of genotype A. Whether APOBEC3G could also inhibit the replication of HBV with different genotypes (genotypes B and C) from clinical isolates is a great concern. As we expected, pXF3A3G could also inhibit the replication of the most prevalent genotypes B and C from clinical isolates to a similar extent as on pHBV1.3, thereby indicating the inhibitory effect of APOBEC3G is different than that of the siRNAs which is sequence-specific.

The hydrodynamic delivery of nucleic acids in the mouse was described by Liu et al\cite{31}, who showed that the vast majority of the injected nucleic acid was delivered to the liver by this technique. Yang et al\cite{32} first demonstrated that hydrodynamic injection of a replication-competent HBV vector resulted in high levels of HBV replication in the livers of the injected mice. In the vector-based model, HBV replicates in the liver of immunocompetent mice for 7-10 d, resulting in detectable levels of HBV RNA and antigens in the liver and of HBV DNA and antigens in the serum. Several reports have documented the use of the HBV vector model to examine the in vivo activity
of co-HDI-administered HBV-targeted unmodified siRNAs[34,35] or vector-expressed short hairpinRNAs[36] in silencing HBV gene expression. Most notably, we have demonstrated in vitro activity of APOBEC3G and its N-terminal or C-terminal cytosine deaminase domain expression vector via standard intravenous administration. This is probably the first demonstration of APOBEC3G in vitro activity in a hepatitis animal model with a clinically viable route of administration. Although we observed a more than 50 times reduction in serum HBV levels after treatment with APOBEC3G and its N-terminal or C-terminal cytosine deaminase domain in an HBV mouse model, the potential contribution of toxicity from the APOBEC3G has not been ruled out and will need to be investigated further.

During the course of an acute infection, HBV DNA clearance apparently occurs through noncytopathic mechanisms in which interferon γ (IFN-γ) and tumor necrosis factor α (TNF-α) play an important role[37,38]. APOBEC3G might participate in this type of antiviral response. Although APOBEC3G is not normally expressed in the liver, but a recent study has shown that APOBEC3G is induced by IFN-α stimulation in human hepatocytes[39]. It is possible that it is induced by IFN in the course of HBV infection. Several studies have shown that IFNs inhibit HBV replication in vitro and in vivo in human hepatoma cells and HBV transgenic mice[40-42]. Currently, IFN-α is an approved treatment for chronic hepatitis B. We speculate that APOBEC3G might be responsible for the anti-HBV action of IFNs under hepatic inflammation. Further analyses will be necessary to determine whether APOBEC3G plays roles in the human innate defense against hepatitis viruses in vivo.

Our study demonstrated that APOBEC3G and its N-terminal and C-terminal cytosine deaminase domain effectively inhibited HBV replication in the culture cells and mammalian liver, showing that such an approach could be useful in the treatment of HBV infection. However, whether suppression of viral replication by APOBEC3G plays a role during natural HBV infection seems speculative at present, because expression of APOBEC3G in human liver tissue has not yet been shown. Nevertheless, a better understanding of the mechanisms of A3G action may help identify new therapeutic strategies against chronic hepatitis B.

REFERENCES

1. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29-60
2. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129
3. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64: 51-68
4. Schumacher AJ, Nissley DV, Harris RS. APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast. Proc Natl Acad Sci USA 2005; 102: 9854-9859
5. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418: 646-650
6. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003; 424: 99-103
7. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 2003; 424: 94-98
8. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH. DNA deamination mediates innate immunity to retroviral infection. Cell 2003; 113: 803-809
9. Esnault C, Heidmann O, Delebecque F, Dewannieux M, Ribet D, Hance AJ, Heidmann T, Schwartz O. APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retrovirus. Nature 2005; 433: 430-433
10. Dutko JA, Schäfer A, Kenny AE, Cullen BR, Curcio MJ. Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases. Curr Biol 2005; 15: 661-666
11. Simon JH, Gaddis NC, Fouchier RA, Malim MH. Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat Med 1998; 4: 1397-1400
12. Sheehy AM, Gaddis NC, Malim MH. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 2003; 9: 1404-1407
13. Marin M, Rose KM, Kozak SL, Kabat D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 2003; 9: 1398-1403
14. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003; 302: 1056-1060
15. Liddament MT, Brown WL, Schumacher AJ, Harris RS. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol 2004; 14: 1385-1391
16. Newman EN, Holmes RK, Craig HM, Klein KC, Lingappa JR, Malim MH, Sheehy AM. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol 2005; 15: 166-170
17. Guzavo F, Bollman B, Chen H, Königsig R, Yu Q, Chiles K, Landau NR. Complementarity function of the two catalytic domains of APOBEC3G. Virology 2005; 333: 374-386
18. Chiu YL, Soros VB, Kreibergs JF, Stopak K, Yonemoto W, Greene WC. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 2005; 435: 108-114
19. Turelli P, Mangeat B, Jost S, Vianin S, Trono D. Inhibition of hepatitis B virus replication by APOBEC3G. Science 2004; 303: 1829
20. Röslcker C, Kück J, Malim MH, Blum HE, von Weizsäcker F. Comment on “Inhibition of hepatitis B virus replication by APOBEC3G”. Science 2004; 305: 1403; author reply 1403
21. Jarmuz A, Chester A, Bayliss J, Gisbourne J, Dunham I, Scott J, Navaratnam N. An anthropoid-specific locus of orphan C to U RNA-editing enzymes. Curr Biol 2004; 14: 259-262
22. Wedekind JE, Dance GS, Sowden MP, Smith HC. Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. Trends Genet 2003; 19: 207-216
23. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999; 6: 1258-1266
24. Zhang G, Budker V, Wolff JA. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther 1999; 10: 1735-1737
25. Pugh JC, Yaginuma K, Kolk K, Summers J, Duck hepatitis B virus (DHBV) particles produced by transient expression of DHBV DNA in a human hepatoma cell line are infectious in vitro. J Virol 1988; 62: 3513-3516
26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408
27. Lei YC, Yao YH, Zhang ZM, Tian YJ, Wang BJ, Yang Y, Zhao XP, Lu M, Gong FL, Yang DL. Inhibition of hepatitis B virus replication by APOBEC3G in vitro and in vivo. World J Gastroenterol 2006; 12: 4492-4497
28 Kidd-Ljunggren K, Miyakawa Y, Kidd AH. Genetic variability in hepatitis B viruses. J Gen Virol 2002; 83: 1267-1280
29 Günther S, Li BC, Miska S, Krüger DH, Meinel H, Will H. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol 1995; 69: 5437-5444
30 Yang PL, Althage A, Chung J, Chisari FV. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci USA 2002; 99: 13825-13830
31 Nguyen SL, Hallet R, Teo CG. Natural and iatrogenic variation in hepatitis B virus. Rev Med Virol 2002; 12: 381-388
32 Oon CJ, Lim GK, Ye Z, Goh KT, Tan KL, Yo SL, Hopes E, Harrison TJ, Zuckerman AJ. Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine 1995; 13: 699-702
33 Haché G, Liddament MT, Harris RS. The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J Biol Chem 2005; 280: 10920-10924
34 Giladi H, Ketzinel-Gilad M, Rivkin L, Felig Y, Nussbaum O, Galun E. Small interfering RNA inhibits hepatitis B virus replication in mice. Mol Ther 2003; 8: 769-776
35 Klein C, Bock CT, Wedemeyer H, Wüstefeld T, Locarnini S, Dienes HP, Kubicka S, Manns MP, Trautwein C. Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology 2003; 125: 9-18
36 McCaffrey AP, Nakai H, Pandey K, Huang Z, Salazar FH, Xu H, Wieland SF, Marion PL, Kay MA. Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 2003; 21: 639-644
37 Biermer M, Puro R, Schneider RJ. Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid integrity through activation of NF-kappB. J Virol 2003; 77: 4033-4042
38 Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001; 19: 65-91
39 Tanaka Y, Marusawa H, Seno H, Matsumoto Y, Ueda Y, Kodama Y, Endo Y, Yamauchi J, Matsumoto T, Takaori-Kondo A, Ikai I, Chiba T. Anti-viral protein APOBEC3G is induced by interferon-alpha stimulation in human hepatocytes. Biochem Biophys Res Commun 2006; 341: 314-319
40 Hayashi Y, Koike K. Interferon inhibits hepatitis B virus replication in a stable expression system of transfected viral DNA. J Virol 1989; 63: 2936-2940
41 Tur-Kaspa R, Teicher L, Laub O, Itin A, Dagan D, Bloom BR, Shafritz DA. Alpha interferon suppresses hepatitis B virus enhancer activity and reduces viral gene transcription. J Virol 1990; 64: 1821-1824
42 Gilles PN, Fey G, Chisari FV. Tumor necrosis factor alpha negatively regulates hepatitis B virus gene expression in transgenic mice. J Virol 1992; 66: 3955-3960

S-Editor Wang GP  L-Editor Kumar M  E-Editor Bai SH